Company profile
TherapeuticsMD, Inc.
NASDAQ: TXMD · Healthcare · Drug Manufacturers - Specialty & Generic
#756 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
60CFH 64DQ 69GM 38SS 42
v0.1 · 65/100 weight · provisional
↑ Piotroski F, disclosure history · ↓ workforce scale, 3-yr revenue growth
Methodology →Revenue TTM
$3.4M
Rev growth YoY (TTM)
+82.1%
Net income (FY)
-$569.0k
Employees
1
as of 2026-08-21
Market cap
$23.8M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.0M$3.0M2025
Net income-$569.0k-$569.0k2025
Operating income-$4.4M-$4.4M2025
Total assets$37.7M$37.7M2025
Liabilities$10.8M$10.8M2025
Equity$26.9M$26.9M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is TherapeuticsMD, Inc.’s revenue?
TherapeuticsMD, Inc. booked $3.0M in FY2025 revenue, growing 72% year over year — faster than most Healthcare companies we track, at a -18.8% net margin.
Peers · Healthcare
Numinus Wellness Inc.——Intelligent Bio Solutions Inc.40DNet Medical Xpress Solutions, Inc.——Xenetic Biosciences, Inc.56CPeakBirch Commerce Inc.——Protara Therapeutics, Inc.43DNeighbors
Palm Beach →Key facts
CEOMarlan D. Walker
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersBoca Raton, FL
ExchangeNASDAQ: TXMD
Employees1
IPO date2007-05-09
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.